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ABSTRACT 
Objective: Ivabradine hydrochloride (IH), a benzazepine derivative used to treat cardiovascular disease angina pectoris. In this study IH-loaded 
novel carrier systems transfersomes (TFs) and conventional liposomes (CLs) were developed and compared for their efficacy to enhance the 
stability of drugs from degradation.  
Methods: TFs formulations (TF-1, TF-2 and TF-3) were prepared by using different biocompatible surfactants; tween-80 (TW), span-80(S) and 
sodium deoxycholate (SC) in the concentration ratio of 15 parts with 85 parts of soy phosphatidylcholine as phospholipid by thin-film hydration 
method. These vesicles were compared with CLs formulation (L-1) prepared in 7:3 molar ratio of soy phosphatidylcholine: cholesterol by following 
the same method. These vesicles were compared for physical appearance, vesicle shape, and size, percentage drug entrapment efficiency (%DEE), 
deformability index (DI), in vitro percentage cumulative drug release study, and physical stability studies. The chosen optimized novel carriers were 
observed under scanning electron microscopy. 
Results: The compared data demonstrated that the physical appearance for all vesicles was turbid and had a spherical shape. The size distribution 
was in the range of 129.0 nm to 273.5 nm in vesicles. The %DEE (79.0±0.94) and DI (35.0±1.9) was found maximum in TF-1 formulation that was 
2.3 times higher than L-1 formulation. The in vitro percentage cumulative drug release study followed second-order polynomial kinetics that was 
2.0 times higher than L-1and 2.9 times higher than the plain drug in 30 min (90.4±0.06%) from TF-1. The vesicles were found to be stable at 
refrigeration conditions.  
Conclusion: Thus, amongst of all vesicles TW loaded TFs (TF-1) was chosen as an excellent novel vesicular carrier for hydrophilic drugs due to its 
higher deformability behavior than CLs that protects the certain drugs from biodegradation and provides stability.  
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INTRODUCTION 
IH, an inhibitor of the If pacemaker current, selectively targets the 
heart rate and to beta-blockers that does not reduce myocardial 
contractility or relaxation [1]. It is a hydrophilic drug (≥5 mg/ml) 
and having short biological half-life used for patients with normal 
sinus rhythm and heart rate ≥ 70 beats per minute and who are 
contraindicated to the use of beta-blockers. Results of a post-
marketing surveillance study in thousands of patients, where 
therapy with Ivabradine tablets was associated with a significant 
reduction in the frequency of angina attacks and consumption of 
short-acting nitrates of 87%. This includes an increase in myocardial 
diastolic perfusion time [2], enhancement in coronary flow reserve 
[3], and improvement in endothelial function [4] in patients with 
chronic stable coronary artery disease [5]. IH is effective and safe in 
all subpopulations of angina patients seen in clinical practice, 
independent of age, comorbidities, and use of beta-blocker in 
tolerated doses but treatment was withdrawn because of adverse 
effects in 7% of patients. The most common adverse effects 
responsible for withdrawal were luminous phenomena (14.5%), 
bradycardia (2%), headaches (2.6-4.8 %) [6]. Thus, to overcome 
these problems a carrier-based system loaded with the drug was 
proposed. The vesicular carriers TFs and CLs were developed and 
compared for their effectiveness in the present work. Vesicles 
consist of hydrophobic and hydrophilic moieties together and can 
accommodate drug molecules of higher molecular weight. These bi-
layer vesicles have the ability to overcome the permeation difficulty 
by squeezing themselves along the inter-cellular sealing lipid of the 
stratum corneum [7]. TFs having flexible membrane by phospholipid 
and surfactants in the proper ratios that minimize the risk of 
complete vesicle rupture. They can deform and pass through narrow 
constriction from 5 to10 times less than their own diameter. These 
are the biocompatible and biodegradable carrier for low and high 
molecular weight drugs e. g. analgesic, anesthetic, corticosteroids, 
hormones, anticancer, insulin, gap junction protein, and albumin [8]. 
The CLs are microscopic spherical particles in which membranes 
having one or more lipid bilayer and encapsulate a fraction of drug 
dispersion [9]. These have high membrane fluidity, which promotes 
penetration of the drug into deeper layers of the skin and can deliver 
a large quantity of hydrophilic and lipophilic drugs, proteins, and 
macromolecules through the skin [10]. Thus, the present study was 
aimed at the preparation and comparison of IH loaded TFs and CLs 
vesicular system.  
MATERIALS AND METHODS 
Materials 
The IH drug was generously gifted by Ind swift Ltd., Chandigarh, 
India. Cholesterol (From CDH fine chemicals), Soy 
phosphatidylcholine (from bright laboratories) and tween-80 (TW), 
span-80 (S), sodium deoxycholate (SC) from Merck specialist, 
Mumbai was purchased. All other chemicals and solvents used in 
this study were of analytical grade. Freshly prepared distilled water 
was used throughout the studies. 
Methods 
Estimation of IH 
The drug IH was estimated by ultraviolet (UV) spectrophotoscopic 
method (UV-2400 PC series, Shimadzu, Japan) at 286.0 nm 
absorbance in phosphate buffer (pH 6.8) [11]. The calibration curve 
was prepared in the concentration range 10-55 µg/ml that followed 
Lambert-beer law.  
Preparation of vesicles  
Vesicles TFs were prepared by a thin-film hydration method [12] 
with some modification. Precisely, the 85 parts of surfactants; TW, S, 
and SC were mixed separately with 15 parts of soy 
phosphatidylcholine in 3 clean, dry round bottom flasks marked as 
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TF-1, TF-2, and TF-3 respectively. The mixture of chloroform: 
methanol (2:1 v/v) 20 ml was added gradually in each flask by 
shaking slowly to prepare a suspension. The organic solvent was 
evaporated by a rotary evaporator and under vacuum overnight. 
The 10% v/v ethanol in phosphate buffer solution (pH 6.8) was used 
as hydrating media to hydrate the dried thin film by rotation at 60 
rpm for 1h at room temperature. The resulting vesicles were 
swollen for 2 h at room temperature to get large multi-lamellar 
vesicles. This thick suspension was broken by shaker (Jyoti scientific 
industry, India), sonicated (Soniwel, India) for half an hour at 4 °C 
and extruded through 200 nm and 450 nm polycarbonate 
membranes (Millipore). The saturated concentration of the drug was 
incorporated in prepared vesicles.  
The CLs were prepared by dissolving Soy phosphatidylcholine: 
cholesterol (7:3 molar ratios) by the same method as described 
above for comparison in the present work and marked as L-1. 
Evaluation of prepared vesicles 
Morphology and mean vesicle size  
For this study, a thin film of prepared vesicles was spread on a slide 
and a coverslip was placed over it and observed under the optical 
microscope (Olympus, India) using a 45X lens in triplicate [13]. 
Physical appearance  
The vesicular sample (10 ml) from each formulation was diluted 
with 5 ml of distilled water and sonicated for 5 min and observed 
against the black background and reported turbidity as dense and 
colloidal form.  
Percentage of drug entrapment efficiency 
The percentage drug entrapment efficiency (%DEE) was analyzed by 
centrifugation of prepared vesicles at 22000 rpm at 4 °C for 2 h to 
obtain the pellets of vesicles and the supernatant containing the free 
drug. These pellets were washed with distilled water to remove any 
unentrapped drug by centrifugation. The drug content was analyzed 
in the supernatant after suitable dilution with phosphate buffer 
solution (pH 6.8) by measuring absorbance at 286 nm. The same 
procedure adopted for CLs drug entrapment as control. The %DEE 
was calculated statistically in three trial by following the equation-
%DEE = D1−D2
D1
100, Where, D1= Initial amount of drug added,  
D2= Amount of drug in the filtrate, (D1–D2) = Amount of entrapped 
drug [14].  
Deformability index 
Deformability Index (DI) was measured in all vesicles by the 
extrusion method by using a filter membrane having a pore size 
diameter of 100 nm. A stainless steel filter holder having a 50 mm 
diameter has been used at 2.5 bar pressure. The extruded quantity 
of vesicles suspension in 5 min was measured by using equation 
[15] Ev = J(vs
pd
)2. Where, Ev=Elasticity of vesicles membrane, J = 
Extruded amount of suspension in 5 min, vs = Vesicles size, pd = 
pore diameter. Data were recorded statistically to follow mean±SD 
in triplicate. 
In vitro percentage cumulative drug release studies 
Prepared formulations TF-1, TF-2, and TF-3 were investigated under 
In vitro percentage cumulative drug release studies. In this study 
treated cellophane membrane was used as a dialysis membrane. It 
was tied on the mouth of each dialysis tube having a surface area of 
4.50 cm2 and diffusion conditions were maintained and set up the 
assembly on a magnetic stirrer at 100 rpm. Phosphate buffer (pH 
6.8) was used as receptor media at 37 °C. Each 10 mg vesicle sample 
was placed on the cellophane membrane and this assembly was 
touched onto the dissolution medium surface. Samples were 
withdrawn 2 ml at regular intervals of 10 min and replaced with the 
same amount of receptor media. The same procedure was adopted 
for plain drug solution and L-1 formulations as control. Collected 
samples were suitably diluted with buffer solution up to 3 h and 
analyzed at 286.0 nm using phosphate buffer (pH 6.8) as blank. The 
study was conducted in the statistical significance of mean±SD in 
each of the three trials.  
The equation %Drug released = released amount of drug at time t
Initial amount of drug
100, was 
used to estimate percentage drug release kinetics quantitatively.  
Stability studies 
A protocol of stability study was carried out with some 
modifications to examine the aggregation and leakage from 
prepared vesicles formulations throughout storage [16]. Vesicle 
formulations were stored in airtight amber colored glass vials 
(Three each) at refrigeration temperature (4±2) °C, room 
temperature (25±2) °C and body temperature (37±2) °C for a period 
of at least 4 mo. After every 15 d, time interval up to 4mo vesicle 
formulations were examined for physical appearance, mean vesicle 
size, and mean %DEE of the drug. Statistical estimation was done as 
mean±SD [17]. 
Scanning electron microscopy study 
The morphology of the drug IB and selected optimized vesicular 
carrier (TF-1) were observed by scanning electron micrographs 
(SEM) using Joel Scanning electron microscopy JSM-840 with a 10 
kV accelerating voltage. The sample was put on the grid and fixed by 
adhesive and used for photomicroscope, without metal coating. 
RESULTS AND DISCUSSION 
The TFs vesicular formulation (TF-1, TF-2 and TF-3) were 
developed with the incorporation of different kinds of surfactants 
(TW, S and SC): soy phosphatidylcholine at the ratio of 15:85. These 
have different hydrophilic-lipophilic balance values like 15, 4.3, and 
16, respectively. The CLs formulation L-1 was developed with 
cholesterol with Soy phosphatidylcholine phospholipid. Table 1 
showed the formulation compositions of vesicular preparations. 
  
Table 1: Formulation composition of TFs and CLs* 
Formulation TW (%w/w) S (%w/w) SC (%w/w) CHL (%w/w) SPC (%w/w) CF: MT mixture (2:1) ml IH (mg) 
TF-1 15.0 - - - 85.0 20.0 300.0 
TF-2 - 15.0 - - 85.0 20.0 300.0 
TF-3 - - 15.0 - 85.0 20.0 300.0 
L-1 - - - 3.0 07.0 20.0 300.0 
*All formulations were prepared in 10% v/v ethanol in Phosphate buffer (pH 6.8) q. s. to produce 100%w/w, TW= Tween-80, S= Span-80, SC= 
sodium deoxycholate, SPC= Soy phosphatidylcholine, IH= Ivabradine hydrochloride, CHL=Cholesterol, CF: MT=Chloroform: Methanol 
 
The characterization of prepared vesicular formulations was shown 
in table 2. It was found that all vesicles formulations were turbid 
(off-white precipitate) and colloidal against the black background. 
Microscopically spherical morphology was observed in the suitably 
diluted samples of each vesicle. The size distribution of vesicles was 
observed in the range of 129.0±0.21 nm to 273.5±0.20 nm. This 
related to increment in the surface free energy and hydrophilicity or 
lipophilicity of the surfactant molecules [18]. The particle size of 
vesicles was depended on the presence of surfactant and 
phospholipid concentration. Data revealed that the %DEE of 
prepared vesicles TF-1, TF-2, TF-3, and L-1 were found to be 
79.0±0.94, 47.3±0.83, 61.7±0.95, and 34.3±1.21, respectively. Drug 
encapsulation in TF-1 was found to be 2.3 times higher than L-1 
formulation. The drug distribution coefficient between the lipid and 
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aqueous phase affects the entrapment of lipophilic and hydrophilic 
drugs into lipid vesicles [19]. Drug encapsulation was increased due 
to affinity towards hydrophilic surfactant of TW, which was suitable 
to entrap hydrophilic drug IB [20].  
TFs showed deformability character due to having a flexible 
phospholipid bi-layer membrane. This property was not present on 
CLs. When surrounding stress was enforced on the vesicle for 
penetration, spontaneously TFs undergo deformation to avoid the 
risk of structure rupture. The comparative graph had been prepared 
between % DEE and DI (fig. 1). The maximum DI was found in 
formulation TF-1 that is 12.5 times than CLs formulation. 
Deformability of TFs is related to membrane fluidity, which was 
made up of phospholipid and surfactant. They transform bilayer into 
a single layer because having a non-bulky hydrocarbon chain and 
almost linear structure of TW [21]. 
  
Table 2: Characterization of vesicles* 
Formulation  Mean vesicle size (nm)  %DEE DI Physical appearance 
TF-1 129.0±0.21 79.0±0.94 35.0±1.9 +++ 
TF-2 273.5±0.20 47.3±0.83 16.8±1.6 ++ 
TF-3 184.8±0.54 61.7±0.95 31.7±2.1 +++ 
L-1 198.4±0.25 34.3±1.21 2.8±1.3 ++ 
*All values were expressed as (mean±SD, n=3) observations,+= Slightly colloidal,++=Turbid and colloidal,+++=Dense and colloidal 
 
 
Fig. 1: Comparative study of %DEE and DI on vesicular formulations (mean±SD, n=3) 
 
The In vitro percentage cumulative drug release studies through 
dialysis membrane on vesicular formulations were carried out by 
comparing with the plain drug formulation. Data from fig. 2 showed 
that it followed polynomial second order kinetics. The percentage of 
cumulative drug released was found maximum (90.4±0.06%) from 
TF-1 in 30 min. It was 2.0 times higher than L-1and 2.9 times higher 
than the plain drug. Smaller the diameter of the vesicle larger would 
be the surface area. It created a higher concentration of entrapped 
drug release from prepared vesicles. Due to the smaller size of 
prepared TFs of TW with IH and more affinity towards 
hydrophilicity showed higher drug release profile than liposomal 
vesicular formulation. 
  
 
Fig. 2: In vitro percentage cumulative drug released from vesicular formulations (mean±SD, n=3) 
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The physical stability studies of vesicular formulation (TF-1, TF-2, 
TF-3 and L-1) were investigated for %DEE, mean vesicle size, and 
physical appearance up to 4 mo. Table 3 indicated that in 
refrigeration condition (4±2 °C), insignificant changes (p>0.05) in % 
DEE and vesicular size of stored TFs and CLs were detected. The 
color remained as same as off white precipitate. No color changes 
were observed. But, It was found that there were significant changes 
(P<0.05) in %DEE and vesicle size of the vesicular formulations 
stored at (25±2) °C and (37±2) °C. The vesicles were swelled or 
aggregated in the vehicle during the storage period. At higher 
temperature leakage of encapsulated drug from vesicles were 
detected. At higher temperature, pale yellow color and slight 
sedimentation were observed. This could be explained by enhanced 
fluidity of the lipid bilayer of vesicles at the higher temperatures. 
This led to the chemical degradation of phospholipids membrane 
packaging arrangement. Temperature 25 °C or less was found to be 
suitable storage of vesicular formulations. All parameters were 
evaluated statistically. 
 
Table 3: Stability studies of prepared vesicles after four mo 
Formulation Mean %EE at Mean vesicle size (nm) at 
(4±2) ° (25±2) ° (37±2) ° (4±2) ° (25±2) ° (37±2) ° 
TF-1 78.4±0.94 75.4±0.24 74.1±0.17 128.6 134.1 145.3 
TF-2 47.1±0.86 33.6±0.92 29.7±0.81 282.7 294.6 298.1 
TF-3 78.4±0.83 71.1±0.86 69.8±0.82 189.2 193.5 208.7 
L-1 26.4±0.74 20.1±0.99 16.7±0.04 224.5 236.8 239.9 
 * Results expressed as (mean±SD, n=3) 
 
The SEM study of drug IB showed crystalline morphology of the 
drug (fig. 3). On the basis of maximum %DEE, maximum DI, 
maximum percentage cumulative drug release, smaller vesicle size 
and stability than CLs formulation, the optimized TFs carrier from 
formulation TF-1 was selected for SEM that showed spherical shape 
(fig. 4). 
 
 
Fig. 3: SEM of IB expressed as mean±SEM, n=3 
 
 
Fig. 4: SEM of TF-1 expressed as mean±SEM, n=3 
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CONCLUSION 
It was concluded that TFs are excellent drug carriers than CLs due to 
their higher deformability behavior. These are phospholipid 
vesicles, self-optimized aggregates, more elastic with the ultra-
flexible membrane, and are able to deliver the drug reproducibly 
either into or through the skin with high efficiency than CLs. In the 
present study, the encapsulated drug IB was incorporated with 
phospholipid bi-layer and surfactant that enhanced the stability and 
efficacy of the drug. Thus, TFs were the novel vesicular carrier for 
various drugs and served as a potential tool in future dosage 
development.  
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